Xinting Lv1, Li Zhang2, Renjun Huang1, Weiyong Song1. 1. Second Section of The Surgical Department, The First People's Hospital of Yongkang Yongkang 321300, China. 2. Department of Ultrasound, General Hospital of Ningxia Medical University Yinchuan 750004, China.
Abstract
BACKGROUND: Advanced gastric cancer refers to tumor invasion into the gastric muscularis propria or even the layer beyond, and has low early gastric cancer diagnosis rate. PURPOSE: To determine the clinical efficacy and side effects of neoadjuvant chemotherapy with tegafur, gimeracil, and oteracil potassium capsules (TGOP) combined with oxaliplatin (SOX regimen) in patients with advanced gastric cancer. METHODS: We evaluated 25 patients with advanced gastric cancer who were admitted and treated with neoadjuvant chemotherapy with the SOX regimen (intravenous injection of 130 mg/m(2) oxaliplatin on day 1 followed by oral administration of 60 mg TGOP twice daily on days 1-14), every 3 weeks. The clinical efficacy and side effects of the SOX regimen were evaluated after two courses of treatment, before surgery. RESULTS: Of the 25 patients enrolled in this study, 23 completed two courses of neoadjuvant chemotherapy, and of these, 12 achieved downstaging as determined by the clinical TNM stage, resulting in a total response rate of 52.2%. The 23 patients underwent surgery, with 22 receiving radical resection (95.7%). Among these 23 patients, R0 resection was achieved in 16 (69.6%) and pathological complete remission was observed in one. CONCLUSION: Neoadjuvant chemotherapy with TGOP combined with oxaliplatin was effective for advanced gastric cancer and had tolerable side effects.
BACKGROUND: Advanced gastric cancer refers to tumor invasion into the gastric muscularis propria or even the layer beyond, and has low early gastric cancer diagnosis rate. PURPOSE: To determine the clinical efficacy and side effects of neoadjuvant chemotherapy with tegafur, gimeracil, and oteracil potassium capsules (TGOP) combined with oxaliplatin (SOX regimen) in patients with advanced gastric cancer. METHODS: We evaluated 25 patients with advanced gastric cancer who were admitted and treated with neoadjuvant chemotherapy with the SOX regimen (intravenous injection of 130 mg/m(2) oxaliplatin on day 1 followed by oral administration of 60 mg TGOP twice daily on days 1-14), every 3 weeks. The clinical efficacy and side effects of the SOX regimen were evaluated after two courses of treatment, before surgery. RESULTS: Of the 25 patients enrolled in this study, 23 completed two courses of neoadjuvant chemotherapy, and of these, 12 achieved downstaging as determined by the clinical TNM stage, resulting in a total response rate of 52.2%. The 23 patients underwent surgery, with 22 receiving radical resection (95.7%). Among these 23 patients, R0 resection was achieved in 16 (69.6%) and pathological complete remission was observed in one. CONCLUSION: Neoadjuvant chemotherapy with TGOP combined with oxaliplatin was effective for advanced gastric cancer and had tolerable side effects.
Authors: Kazumasa Fujitani; Jaffer A Ajani; Christopher H Crane; Barry W Feig; Peter W Pisters; Nora Janjan; Garrett L Walsh; Stephen G Swisher; Ara A Vaporciyan; David Rice; Angela Welch; Jackie Baker; Josephine Faust; Paul F Mansfield Journal: Ann Surg Oncol Date: 2007-03-08 Impact factor: 5.344
Authors: T Yoshikawa; K Omura; O Kobayashi; A Nashimoto; A Takabayashi; T Yamada; H Yamaue; M Fujii; T Yamaguchi; T Nakajima Journal: Eur J Surg Oncol Date: 2010-06 Impact factor: 4.424
Authors: T Shirasaka; Y Shimamato; H Ohshimo; M Yamaguchi; T Kato; K Yonekura; M Fukushima Journal: Anticancer Drugs Date: 1996-07 Impact factor: 2.248
Authors: V Valenti; J L Hernandez-Lizoaín; M C Beorlegui; J A Diaz-Gozalez; F M Regueira; J J Rodriguez; A Viudez; I Sola; J A Cienfuegos Journal: J Surg Oncol Date: 2011-04-20 Impact factor: 3.454
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Umme Hani; Riyaz Ali M Osmani; Sabina Yasmin; B H Jaswanth Gowda; Hissana Ather; Mohammad Yousuf Ansari; Ayesha Siddiqua; Mohammed Ghazwani; Adel Al Fatease; Ali H Alamri; Mohamed Rahamathulla; M Yasmin Begum; Shadma Wahab Journal: Pharmaceutics Date: 2022-07-29 Impact factor: 6.525